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Guaifenesin and dropropizine were analyzed through oxidation with periodic acid to give formaldehyde which was allowed to
condense with 4-Amino-5-hydrazino-4H [1,2,4]-triazole-3-thiol (AHTT). The condensation product was further oxidized to
yield a purple colored compound with maximum absorption at 550nm. Beer’s law was obeyed in the range of 5–45µgm L
−1
for guaifenesin and 10–80µgm L
−1 for dropropizine. Both drugs were also successfully determined in their dosage forms.
1.Introduction
Guaifenesin (GF), 3-(2-Methoxyphenoxy)-1,2-propanediol;
is reported to increase the volume and reduce the viscosity of
tenacious sputum and is used as expectorant for productive
cough [1]. Diﬀerent methods have been reported for the
analysis of GF including HPLC [2–8], GC [9, 10], capillary
electrophoresis mass spectrometry [11], X-ray diﬀraction
[12], voltammetry [13].
Dropropizine (DP),3-(4-Phenyl-1-piperazinyl)-1,2-pro-
panediol, is a cough suppressant reported to have a periph-
eral action in nonproductive cough [1]. Only two GC-
mass spectrometry methods have been reported for the
determination of DP in biological ﬂuids [14, 15] in addition
to a manufacturer procedure that involves the determination
of dropropizine by measuring its UV absorbance at 237nm
in 0.05N HCl (personal contact):
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The aim of the present paper is to develop a simple
and accurate method for the determination of dropropizine
and guaifenesin that permits their analysis in dosage forms
withoutinterferencefromexcipients and other coformulated
drugs.
2. Experimental
2.1. Chemicals and Reagents. Purpald or 4-Amino-5-hydra-
zino-4H [1,2,4]-triazole-3-thiol reagent (AHTT) (Sigma-
Aldrich) was prepared as 0.5% in 0.5M hydrochloric acid.
Periodic acid (Winlab, UK.) was prepared as 1mg mL
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solution in 0.2M potassium hydroxide. HPLC grade acetoni-
trile was from Fisher Scientiﬁc, UK. Potassium dihydrogen
phosphate was from Sigma-Aldrich Chemie, Germany. All
other chemicals used were of analytical grade and water was
freshly distilled.
2.2. Materials. Reference standard guaifenesin (GF),
dropropizine (DP) and bromhexine HCl (BR) were kindly
supplied by Rameda Co. for pharmaceutical industries and
diagnostic reagents, EVA Pharma for pharmaceutical and
medical appliances and EVA Pharma for pharmaceutical and
medical appliances, respectively.
2.3. Pharmaceutical Preparations
Muclear Capsules: It is a product of Rameda Co., Batch
No. 08455, claimed to contain 100mg guaifenesin and 8mg
bromhexine HCl.
TussapineLozenges: ItisaproductofEVAPharma,BatchNo.
602170, claimed to contain 20mg dropropizine.
2.4. Standard Drug Solutions
Solutions of Guaifenesin: 0.1mg mL
−1 solution of GF was
prepared in distilled water. Aliquots of this solution were
diluted to produce working solutions of 5–45µgm L
−1.
Solutions of Dropropizine: 0.1mg mL
−1 solution of DR was
prepared by in distilled water. Aliquots of this solution were
diluted to produce working solutions of 10–80µgm L
−1.
Solutions of Bromhexine HCl: 0.1mg mL
−1 solution of BR
was prepared in methanol. Aliquot of this solution was
diluted to produce working solution of 50µgm L
−1.
2.5. Instrumentation
(i) Shimadzu UV/VIS 1602 Spectrophotometer.
(ii) Agilent 1200 series isocratic quaternary pump HPLC
instrument connected to 1200 multiple wavelength
UV detector (Germany). Separation was performed
on 150 × 4.6mm Zorbax Extend-C18 column 5µm
particle size (USA). Chromatographic peaks were
electronically integrated and recorded using Chem-
station software.
(iii) pH/mv Meter with double junction glass electrode
(Fisher, USA).
2.6. General Procedure
2.6.1. Calibration. One mL of each working solution of both
drugs was transferred in a test tube, then 1mL periodic
acid was added. The mixture was left at room temperature
for 15 minutes for GF and 20 minutes for DR, 0.5mL 5M
KOH solution was then added followed by 1mL of AHTT
solution. The mixture was shaken and allowed to stand for
about 15 minutes for GF and 20 minutes for DR. Absorbance
of the resulting solution was measured at 550nm, against
blankexperiment.Calibrationcurvesrelatingtheabsorbance
at 550nm to GF or DR concentrations were plotted and
regression analysis of the results was computed.
2.6.2. Assay of Dosage Forms
Muclear Capsules. The well mixed powdered content of
ﬁve capsules was used in the assay. An amount equivalent
to 10mg of GF was transferred into 100mL volumetric
ﬂask, dissolved in distilled water then adjusted to volume
and treated as previously mentioned under calibration
procedure.
TussapineLozenges. Fivetabletsweregroundedtoahomoge-
nous ﬁne powder, weighed and the average mass per tablet
was determined. The amount of powder equivalent to 10mg
of DR was dissolved into 70mL of distilled water. The
solution was sonicated for about ﬁve minutes then ﬁltered
to separate insoluble excipients. Afterwards, the ﬁltrate was
accurately collected into 100mL calibrated ﬂask and diluted
to volume with water. The obtained solution labeled to
contain 0.1mg mL
−1 of each drug was analyzed by the
proposed method as detailed under calibration.
3. Results and Discussion
s-Triazoles have been utilized to produce reagents that can
react with drugs containing carbonyl group or susceptible to
oxidation with periodic acid to produce carbonyl function
such as diols and amino alcohols. In the present work,
guaifenesin and dropropizine were converted into formalde-
hyde and the corresponding carboxylic acids by the selective
oxidizing eﬀect of periodic acid. The liberated aldehyde
wasallowed to reactwith 4-Amino-5-hydrazino-4H [1,2,4]-
triazole-3-thiol, which is a speciﬁc reagent for aldehydic
functional group [16].
When AHTT was allowed to condense with formalde-
hyde followed by treatment with periodic acid and alkali
addition, [1,2,4]-triazolo-[1,2,4,5] tetrazine-3-thiol col-
ored product was obtained as shown in Scheme 1.
3.1.OptimizationofConditions. As reported by Jacobsenand
Dickinson [16], the reaction involves the addition of alkaline
solution of AHTT to the aldehyde solution and aerating the
reaction mixture to give a purple-colored product. Mimura
et al. [17] modiﬁed the procedure of color development by
theuseofperiodicacidasoxidizingagentinsteadofaeration.
In the present study, periodic acid has a dual function.
It acts as a selective oxidizing agent for polyhydroxy com-
pounds to convert them to formaldehyde and correspond-
ing carboxylic acids and help in the development of the
purple colored product according to Mimura et al. [17]
modiﬁcation. It is important to emphasize that Jacobsen and
Dickinson [16] used alkaline solution of AHTT (1% in 1M
NaOH) for color production with aldehydes. However, this
procedure was modiﬁed by using acidic solution of AHTTInternational Journal of Analytical Chemistry 3
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Scheme 1: Reactions involved in analysis of guaifenesin and dropropizine.
(0.5% in 0.5M HCl) which oﬀers two advantages, the ﬁrst
was the use of lower concentration of the reagent; the second
was the higher stability of AHTT solution as mentioned by
Mimura et al. [17].
As reported for colorimetric determination of some
diol-containing drugs [18], solution of guaifenesin and
dropropizine was left for some time, then 5M KOH and
AHTT solutions were added whereby a purple color was
developed with maximum absorption at 550nm (Figures
1 and 2). Maximum color intensity was obtained when
periodic acid solution was made to react with guaifenesin for
15 minutes and dropropizine for 20 minutes.
The eﬀect of periodic acid concentration was also
studied, it was found to be critical the use of 1mg mL
−1
solution of periodic acid in 0.2M KOH produces maximum
color intensity. Excess acid concentration causes a great
decrease in the intensity of the produced color which may
be attributed to the strong oxidizing eﬀect of periodic acid
on both drugs which may proceed to give further oxidation
products.
TheeﬀectofAHTTconcentrationwasalsostudiedwhere
maximumintensitywasobtaineduponusingAHTTsolution
of 0.5% in 0.5M HCl.
VolumeofKOHaddedwasfoundtobecritical;0.5mLof
5M alkali solution was the optimum volume.
Shakingofthereactionmixturefor4-5minuteswasesse-
ntial and produced maximum color intensity after addition
of AHTT solution and waiting period of 15 minutes for GF
and 20 minutes for DR. The obtained color remained stable
for about 40 minutes with both drugs.
3.2. Method Validation
3.2.1. Linearity, Detection, and Quantitation Limits. Cali-
bration curves representing the relation between each drug
concentrations and absorbance of colored products were
constructed. Results show linear relationship in the range of
5–45µgmL
−1 forGFand10–80µgmL
−1 forDR;intriplicate
measurement from which linear regression equations were
calculated. Correlation coeﬃcient, slope and intercept were
listed in Table 1. Results indicate high sensitivity of the
proposed method.
According to ICH recommendation [19], the approach
based on the S.D. of the response and the slope was used
for determining the detection and quantitation limits. The
theoretical values were assessed practically and given in
Table 1.
3.2.2. Accuracy. Accuracy of the measurements was deter-
mined using the calibration standards of two drugs, where
mean percentage of 100.58 for GF and 100.22 for DR
were obtained, results are shown in Table 1.A c c u r a c yw a s
also assessed by the recovery of added standard, three
concentrations each in duplicate to know concentration4 International Journal of Analytical Chemistry
Table 1: Selected spectral data for the determination of guaifenesin and dropropizine by the proposed colorimetric method.
Parameters GF DR
Linearity range (µgm L
−1) 5–45 10–80
Slope ± S.E 0.021 ±3.7E-04 0.011 ± 1.77E-04
Intercept ± S.E. 0.014 ±0.0109 0.039 ±0.0089
Correlation coeﬃcient 0.998 0.998
Accuracy ± S.D. precision 100.58 ±0.48 100.22 ±1.36
Injection repeatability (n = 15) 0.80–1.26 0.14–0.38
Assay reproducibility intraday (n = 9) Muclear Tussapine
0.40%–1.79% 0.13%–0.28%
Interday (n = 27) Muclear Tussapine
1.01%–1.72% 0.39%–0.73%
LOQ
a (µgm L
−1)4 7
LOD
a (µgm L
−1)2 . 5 4 . 5
aLOQ and LOD were done practically.
Table 2: Statistical analysis of the results obtained by applying the proposed, reported and manufacturer methods for the analysis of GF and
DR in their dosage forms.
Preparation Proposed Reported Manufacturer
Muclear
100.34 ± 0.89∗ 101.18 ± 0.76 —
F = 2.71 —
t = 0.55 —
Standard addition 99.39 ± 1.36∗∗
Tussapine
100.29± 0.76∗ — 100.23± 0.84
F =1.55 —
t = 0.33 —
Standard addition 100.60 ± 1.05∗∗
∗Mean of nine determinations (three conc. each in triplet).
∗∗Mean of six determinations (two for each of conc.).
of dosage forms using the proposed colorimetric method.
Results of mean % recovery for added standards in each
formulation are reported in Table 2.
3.2.3. Precision. Repeatability and reproducibility of the
instrumentalresponse(absorbanceoftheformedcolor)were
checked during method development and they were assessed
from ﬁve replicate determinations of sample solutions of GF
a n dD Ra tt h ec o n c e n t r a t i o no f3 0µgm L
−1.
3.2.4. Speciﬁcity. The proposed method was applied for
the determination of both drugs in their pharmaceutical
formulations; results presented in Table 2 revealed that there
is no interference from excipients, additives or coformulated
drugs such as bromhexine HCl present in Muclear capsules
along with guaifenesin. In addition the recoveries of the
studied drugs from their formulations were almost the same
as the recoveries of the pure added when applying the
standard addition technique.
Results obtained by the proposed method were statisti-
cally compared with those obtained from the reported HPLC
method for GF [5] and UV manufacturer method for DR.
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Figure 1: Absorbance spectrum of the colored product produced
from the reaction of AHTT and 30µgm L
−1 guaifenesin.
The calculated t and F values are less than the tabulated ones
indicating no signiﬁcant diﬀerence between the proposedInternational Journal of Analytical Chemistry 5
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Figure 2: Absorbance spectrum of the colored product produced
from the reaction of AHTT and 40µgm L
−1 dropropizine.
andreportedmethodswithrespecttoaccuracyandprecision
at 95% conﬁdence limit (Table 2).
4. Conclusion
The proposed colorimetric method is selective for polyhy-
droxyaliphaticcompounds,simpleandrapidasittakesfrom
15to20minutesforthesampletobereadyformeasurement.
Validationoftheproposedmethodwascarriedoutaccording
to the ICH guidelines. The short duration of the assay
and its speciﬁcity were clear bonuses for routine analysis
of guaifenesin and dropropizine in their pharmaceutical
formulations and in-process quality control.
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